- Details
- Ashish Kamat hosts Roberto Contieri, who shares his work on active surveillance as a treatment approach for low-risk non-muscle-invasive bladder cancer. Highlighting that 75% of bladder cancer patients present with non-muscle-invasive disease, he explores the merits of a conservative approach, noting its cost-effectiveness, safety, and minimal surgical risk. Contieri presents findings from the BIA...
|
- Details
- Stephen Williams and Sam Chang discuss the relationship between Agent Orange and bladder cancer. They highlight a retrospective cohort study conducted on over 25 million veterans to determine the association between Agent Orange exposure and bladder cancer incidence. The study controlled for various factors and found a slight increase in bladder cancer risk among veterans exposed to Agent Orange....
|
- Details
- Sam Chang is joined by Chad Ritch for a discussion on tumor biomarkers and urothelial carcinoma. They discuss various types of biomarkers, including tissue-based and liquid-based markers. In the context of non-invasive bladder cancer, they mention the use of cytology as the standard despite its limitations in sensitivity. They also highlight the potential of RNA-based urinary biomarkers, such as C...
|
- Details
- Katie Murray joins Ashish Kamat discusses optimizing care for bladder cancer in women. Dr. Murray highlights the need to understand the biologic and diagnostic differences, as well as the timing of diagnoses and survival disparities in bladder cancer among women. She emphasizes the importance of raising awareness among primary care physicians and advocating for early diagnosis, as women often expe...
|
- Details
- Sam Chang is joined by Patrick Soon-Shiong for a discussion on the effectiveness of N-803 for BCG unresponsive bladder cancer. They discussed the importance of an ideal profile for such an agent, which includes complete remission rate, durability of the response, and high cystectomy avoidance rate. They also highlighted the importance of the agent's safety and tolerability for urologists. The N-80...
|
- Details
- Roger Li joins Ashish Kamat to discuss the CG0070 adenovirus vector and its potential use in combination with immune checkpoint blockade for patients with BCG unresponsive bladder cancer. The combination therapy has shown promising preliminary results, with 20 out of 22 patients achieving a complete response at three months and six out of eight patients maintaining a complete response at 12 months...
|
- Details
- Amir Horowitz joins Ashish Kamat to talk about his Bladder Cancer Translational Clinical Trial Award. An award given by the Bladder Cancer Advocacy Network (BCAN) aims to support early-phase patient-oriented research to transform bladder cancer care. The ENHANCE Trial is a phase II, single-arm trial starting with high-grade non-muscle-invasive bladder cancer (NMIBC) patients having received and fa...
|
- Details
- Sarah Psutka talks with Ashish Kamat about her Bladder Cancer Translational Clinical Trial Award. An award given by the Bladder Cancer Advocacy Network (BCAN) aims to support early-phase patient-oriented research to transform bladder cancer care. The "Get Moving Trial" is a phase I/II trial of a home-based pre and rehabilitation intervention for muscle-invasive bladder cancer with the use of an ap...
|
- Details
- Manish Patel joins Sam Chang to discuss the development of centers of excellence for the treatment of major urological cancers, specifically focusing on radical cystectomy. He explains how the UK's centralization of radical cystectomy in 2002 led to significant improvements in care and better survival rates. In Australia, 50 centers were doing radical cystectomies, but 39 were doing less than four...
|
- Details
- Ewan Gibb, a PhD scientist, discusses the Decipher Bladder clinical test, a molecular subtyping assay for bladder cancer that predicts the risk of upstaging, identifies high-risk neuroendocrine-like disease and determines the benefit from neoadjuvant chemotherapy. The test breaks a patient's tumor into one of five subtypes and recognizes luminal and non-luminal categories, with neuroendocrine bein...
|
